Kala Bio Inc (KALA)
6.59
-0.14
(-2.08%)
USD |
NASDAQ |
May 17, 16:00
6.59
0.00 (0.00%)
After-Hours: 20:00
Kala Bio Price to Book Value: 2.458 for May 17, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 2.458 |
| May 16, 2024 | 2.526 |
| May 15, 2024 | 2.536 |
| May 14, 2024 | 2.577 |
| May 13, 2024 | 2.558 |
| May 10, 2024 | 2.590 |
| May 09, 2024 | 2.520 |
| May 08, 2024 | 2.657 |
| May 07, 2024 | 2.597 |
| May 06, 2024 | 2.605 |
| May 03, 2024 | 2.630 |
| May 02, 2024 | 2.535 |
| May 01, 2024 | 2.556 |
| April 30, 2024 | 2.560 |
| April 29, 2024 | 2.571 |
| April 26, 2024 | 2.365 |
| April 25, 2024 | 2.320 |
| April 24, 2024 | 2.402 |
| April 23, 2024 | 2.464 |
| April 22, 2024 | 2.376 |
| April 19, 2024 | 2.473 |
| April 18, 2024 | 2.556 |
| April 17, 2024 | 2.567 |
| April 16, 2024 | 2.571 |
| April 15, 2024 | 2.627 |
| Date | Value |
|---|---|
| April 12, 2024 | 2.702 |
| April 11, 2024 | 2.702 |
| April 10, 2024 | 2.759 |
| April 09, 2024 | 2.781 |
| April 08, 2024 | 2.86 |
| April 05, 2024 | 2.852 |
| April 04, 2024 | 2.909 |
| April 03, 2024 | 2.920 |
| April 02, 2024 | 2.999 |
| April 01, 2024 | 2.999 |
| March 28, 2024 | 2.991 |
| March 27, 2024 | 2.887 |
| March 26, 2024 | 2.898 |
| March 25, 2024 | 2.909 |
| March 22, 2024 | 2.938 |
| March 21, 2024 | 2.942 |
| March 20, 2024 | 2.923 |
| March 19, 2024 | 2.839 |
| March 18, 2024 | 2.832 |
| March 15, 2024 | 2.769 |
| March 14, 2024 | 2.806 |
| March 13, 2024 | 2.813 |
| March 12, 2024 | 2.784 |
| March 11, 2024 | 2.876 |
| March 08, 2024 | 2.758 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.017
Minimum
Mar 01 2023
13.79
Maximum
Mar 24 2020
3.324
Average
2.912
Median
Oct 31 2019
Price to Book Value Benchmarks
| CEL-SCI Corp | 4.808 |
| AIM ImmunoTech Inc | 2.107 |
| IGC Pharma Inc | 3.942 |
| NovaBay Pharmaceuticals Inc | -- |
| Protalix BioTherapeutics Inc | 2.806 |
Price to Book Value Related Metrics
| PS Ratio | 2.770 |
| Price | 6.59 |
| Earnings Yield | -273.9% |
| Market Cap | 18.45M |